These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 38782182)

  • 1. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
    Huttasch M; Roden M; Kahl S
    Metabolism; 2024 Aug; 157():155937. PubMed ID: 38782182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
    ; ;
    J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ;
    Diabetologia; 2024 Nov; 67(11):2375-2392. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.
    Giannakogeorgou A; Roden M
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S52-S75. PubMed ID: 38813830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
    Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
    Clin Gastroenterol Hepatol; 2024 Aug; 22(8):1565-1574. PubMed ID: 38367743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
    Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
    Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives.
    Alfieri CM; Molinari P; Cinque F; Vettoretti S; Cespiati A; Bignamini D; Nardelli L; Fracanzani AL; Castellano G; Lombardi R
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
    Puengel T; Tacke F
    Expert Opin Pharmacother; 2024 Jun; 25(9):1249-1263. PubMed ID: 38954663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes.
    Castellano-Castillo D; Núñez-Sánchez MÁ; Balaguer-Román A; Martínez-Sánchez MA; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez CM; Frutos MD; Queipo-Ortuño MI; Cardona F; Ramos-Molina B
    Surg Obes Relat Dis; 2024 Jul; 20(7):652-659. PubMed ID: 38490825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Martínez-Montoro JI; Balaguer-Román A; Murcia-García E; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez-Cáceres CM; Sledzinski T; Frutos MD; Hernández-Morante JJ; Fernández-García JC; Queipo-Ortuño MI; Ruiz-Alcaraz AJ; Mika A; Ramos-Molina B
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1781-1792. PubMed ID: 38217869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.
    Mellemkjær A; Kjær MB; Haldrup D; Grønbæk H; Thomsen KL
    Eur J Intern Med; 2024 Apr; 122():28-34. PubMed ID: 38008609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin-based investigational therapies for the treatment of MASLD/MASH.
    Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
    Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
    Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
    J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease.
    Kjeldsen SAS; Werge MP; Grandt J; Richter MM; Thing M; Hetland LE; Rashu EB; Jensen AH; Winther-Sørensen M; Kellemann JS; Holst JJ; Junker AE; Serizawa RR; Vyberg M; Gluud LL; Wewer Albrechtsen NJ
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G558-G570. PubMed ID: 39104323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The first MASH drug therapy on the horizon: Current perspectives of resmetirom.
    Petta S; Targher G; Romeo S; Pajvani UB; Zheng MH; Aghemo A; Valenti LVC
    Liver Int; 2024 Jul; 44(7):1526-1536. PubMed ID: 38578141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial.
    Stefan N; Hartleb M; Popovic B; Varona R
    Trials; 2024 Jun; 25(1):374. PubMed ID: 38858768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision medicine and nucleotide-based therapeutics to treat MASH.
    Caddeo A; Romeo S
    Clin Mol Hepatol; 2024 Aug; ():. PubMed ID: 39103998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver tissue lipids in metabolic dysfunction-associated steatotic liver disease with diabetes and obesity.
    Sourianarayanane A; Brydges CR; McCullough AJ
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102402. PubMed ID: 38909684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.